Femasys shares are trading lower. The company announced a $30 million private placement.

Femasys Partners With UNC Health To Introduce Fertility Diagnostics, FemVue And SpermVue, Together With Femaseed Complete Within UNC Health OB/GYN Practice Locations

-- For the first time, OB/GYNs within the UNC Health system will be able to offer women FemVue® fertility evaluation and FemaSeed as a first-line treatment option --ATLANTA, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Femasys

Femasys Secures FDA Pathway for Non-Surgical Contraceptive

FDA clears modular PMA pathway for Femasys' FemBloc, an investigational non-surgical permanent birth control device for women in the US.

Femasys shares are trading higher after the company announced that the U.S. Food and Drug Administration has approved the company’s modular premarket approval application pathway for FemBloc.

Femasys Says FDA Approved Modular PMA Pathway For FemBloc Non-Surgical Permanent Birth Control